• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Supreme Cannabis to acquire Truverra as it prepares for Legalization 2.0 and Global Medical Markets

Share:

July 22, 2019

  • Truverra’s Health Canada licensed facility in Toronto, ON to produce cannabis derivative products for Legalization 2.0.
  • Truverra to serve as Supreme Cannabis’ global medical brand, building on existing R&D platform and established CBD offering in Europe .
  • Skilled management team with decades of domestic and international experience in highly regulated industries, including life sciences and pharmaceuticals.

The Supreme Cannabis Company, Inc. (“Supreme Cannabis” or the “Company”) (FIRE.TO) (SPRWF) (53S1.F) today announced that it has entered into a definitive agreement (the “Acquisition Agreement”) under which Supreme Cannabis will acquire all of the issued and outstanding shares of privately-held Truverra Inc. (“Truverra”), to be effected by way of a three-cornered amalgamation between Truverra, Supreme Cannabis and a wholly-owned subsidiary of Supreme Cannabis (the “Transaction”). The Transaction is valued at 14.7 million common shares of Supreme Cannabis (the “Consideration Shares”), giving the Transaction an approximate dollar value of $20,000,000 as of the Company’s closing price on July 16, 2019.

Located in Toronto , Truverra is a private cannabis company, serving the Canadian and international cannabis markets through its wholly-owned subsidiaries, Canadian Clinical Cannabinoids Inc. (“CCC”) and Truverra ( Europe ) B.V. (“Truverra Europe”).

CCC operates a 5,000 square-foot Health Canada licensed facility in Scarborough, Ontario . Supreme Cannabis intends to repurpose CCC’s state-of-the-art facility to produce high-quality cannabis extracts, including concentrates and vaping liquids. In addition to its operations in Canada , Truverra’s wholly-owned European subsidiary, Truverra Europe, is located in the Netherlands and sells a broad portfolio of hemp-based CBD products into select European markets.

“The recent introduction of Health Canada’s amended cannabis regulations creates a distinct opportunity for Supreme Cannabis to establish a leading position in the cannabis extracts markets. With the acquisition of Truverra, we secure a Toronto -based facility equipped to extract our high-quality inputs for concentrates and vaping liquids in the near-term,” said Navdeep Dhaliwal , CEO of Supreme Cannabis. “Truverra’s operations also provide an additional entry point into Europe’s CBD wellness market, where Truverra Europe has successfully launched multiple CBD products in various jurisdictions. Truverra’s Canadian and European operations are managed by a senior leadership team with a wealth of experience manufacturing and launching products in highly-regulated industries such as life sciences and pharmaceuticals.”

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

“The Supreme Cannabis Company has a strong track record for executional excellence, with their support and robust corporate services we look forward to strengthening our operations in Canada and globally,” said Jeff Adams , CEO of Truverra. “In the near term, we will continue to build Truverra’s CBD offering in Europe and position the brand to serve international medical markets.”

Transaction Highlights

Dedicated production capacity for cannabis derivative products.
CCC’s Health Canada-licensed 5,000 square-foot facility in Scarborough, Ontario will house Supreme Cannabis’ extraction lab for concentrates and vaping liquids. Supreme Cannabis will retrofit the facility to include a range of both solvent and solvent-less concentrate and extraction equipment and leverage our unique position as the only cannabis producer with high-end flower at scale. Changes to the facility will commence in the near term with the goal of meeting demand for the pending legalization of concentrates and other derivative cannabis products.

Date: 22/07/2019

Source : Yahoo Finance

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • LeanTaaS Acquires Hospital IQ, Combined Valuation Exceeds $1BLeanTaaS Acquires Hospital IQ, Combined Valuation Exceeds $1B
  • Aiming to change the way people take medicine, Lyndra Therapeutics raises $55 million
  • Graf Acquisition Corp. IV and NKGen Biotech, Inc. Announce Letter of Intent for a Business CombinationGraf Acquisition Corp. IV and NKGen Biotech, Inc. Announce Letter of Intent for a Business Combination
  • Ping An Good Doctor to Develop ‘Internet Hospital’ Model with 50 Hospitals in ChinaPing An Good Doctor to Develop ‘Internet Hospital’ Model with 50 Hospitals in China
  • FDA Recruits Payers to Submit Quality Feedback on Medical DevicesFDA Recruits Payers to Submit Quality Feedback on Medical Devices
  • Healthcare Artificial Intelligence Puts On A Human FaceHealthcare Artificial Intelligence Puts On A Human Face
  • Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period and Extension of Tender Offer to Acquire Acceleron Pharma Inc.Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period and Extension of Tender Offer to Acquire Acceleron Pharma Inc.
  • Smith & Nephew to acquire Atracsys SàrlSmith & Nephew to acquire Atracsys Sàrl

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications